VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI” or “the Company”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it received notice from the Nasdaq Listing Qualifications Office of The Nasdaq Stock Market LLC (“Nasdaq”) on...
Read More
Lot-to-lot manufacturing consistency of Sci-B-Vac®, the primary endpoint, was demonstrated Sci-B-Vac® achieved seroprotection rates of 99.3% and 90.4% after three and two doses, respectively, compared with 94.8% and 51.6% with Engerix-B®, respectively No safety signals observed – safety profile remains...
Read More
33% reduction in tumor size observed in one patient in Part B – reduction sustained through two consecutive MRI scans 6-month overall survival (OS) now available for Part A demonstrated benefit for vaccine responders (100%) vs. non-responders (63%) VBI Vaccines...
Read More
Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection Two-part, dose-escalation study expected to enroll up to 65 patients Initial data expected in H2 2020 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company’s abstract titled, “Interim Results of the Extension Phase of a Phase I/IIa Trial of a Therapeutic CMV Vaccine...
Read More
Final patient visit completed in CONSTANT study of Sci-B-Vac®, on-track for top-line data expected early January 2020 Entered into collaboration with GSK to evaluate the combination of VBI-1901 with GSK’s AS01B adjuvant system in patients with recurrent GBM Initiated enrollment...
Read More
New immunologic and biomarker data from Part A of ongoing Phase 1/2a clinical study of VBI-1901 in recurrent glioblastoma (GBM) patients strengthens correlation between observed vaccine and tumor responses New preclinical data further broadens utility of VBI’s enveloped virus-like particle...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Rapid Increase in Anti-HBsAg Titers and Higher Seroprotection Rates in Adults Immunized with Sci-B-Vac Compared to...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Trivalent hepatitis B (HepB) vaccine yields superior seroprotection rates in adults: results from the phase 3...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option...
Read More